Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Loci Linked to Level of Pain Medication Management Needed

Researchers have identified a handful of genetic loci associated with switching from non-opioid analgesics to opioids in the management of chronic musculoskeletal pain. Treatment typically begins along a three-step ladder with a non-opioid analgesic, then to a weak opioid for mild-to-moderate pain and possibly to a strong opioid for severe pain, but there are many differences between patients, including genetic ones, that could influence the level of medication they need. As they report in the Pharmacogenomics Journal, researchers from Radboud University Medical Center in the Netherlands conducted a genome-wide association study of about 23,000 people from the UK Biobank to find one loci significantly associated with switching from non-opioid analgesics to opioids to manage pain and seven suggestive loci. Four genes implicated by these loci have been tied to neuropathic pain processes or musculoskeletal development, and further network analysis implicated EGFR, though the researchers caution that the input into that analysis consists of nominally significant genes and "should be interpreted carefully." They add that their analysis, which show "a small genetic contribution to analgesic ladder switching," is "an initial stepping stone for future research."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.